Live Microsystems Inc (LMSC): Uptick, we have lots of NOL´s here...

wolfdeluxe · 2014-01-29T16:32:29.9570000Z

Uptick, we have lots of NOL´s here - but i don´t know how much of them they can really utilize - should be quite enough though: "For U.S. federal income tax purposes, the Company has net operating loss carryforwards available to reduce taxable income of $342.1 million at December 31, 2012" If you are further interested, please see my post 837 - there is also a link to the audited report where you can find all the details regarding the NOL´s and more. Given the market cap of 2,28 Mio of today this could be a great opportunity, if LMSC can find a successful partner to merge with - All IMO

Play Episode

11min

Proactive - Interviews for investors

KRM22 CEO on risk management, compliance & growth plans

KRM22 CEO Dan Carter talked with Proactive's Stephen Gunnion about the company’s mission to provide integrated risk management solutions for capital markets. Founded in 2018, KRM22 has developed a suite of tools that help firms manage trading and corporate risk more efficiently. Carter explained that capital markets have traditionally relied on siloed risk tools. KRM22 has worked to integrate these tools into a holistic platform. The company’s solutions cover intraday risk management, pre-trade limit controls, market surveillance, and enterprise risk tracking. “We've created a digitised risk register that helps bring those data points together and validate assessments,” he said. The discussion also covered the impact of regulatory changes post-Covid. Carter highlighted that regulators are now scrutinising risk management practices more closely. He emphasised that KRM22’s tools help firms demonstrate compliance, reducing the risk of regulatory penalties. On growth, Carter noted that KRM22’s annual recurring revenue (ARR) is now around £7 million, with a recent customer contract further strengthening the company’s financial position. Looking ahead, KRM22 is exploring AI-driven enhancements, particularly in market surveillance, to detect potential compliance issues before they become violations. For more insights, watch the full interview. Don't forget to like the video, subscribe to Proactive's channel, and turn on notifications for updates! #KRM22 #RiskManagement #CapitalMarkets #TradingRisk #RegTech #MarketSurveillance #FinancialCompliance #AIinFinance #CorporateRisk #Investing

Proactive - Interviews for investors

Falcon Gold unveils high-resolution drill core images from Great Burnt Copper-Gold Project

Falcon Gold CEO Karim Rayani joined Steve Darling from Proactive to announce the release of high-resolution images from the first two drill holes of its late 2024 exploration program at the Great Burnt Copper-Gold Project in Central Newfoundland. These images, now available on the company's website and social media channels, offer a detailed visual insight into the early drilling results and core recovery quality. Rayani highlighted that the released images showcase detailed core samples, revealing promising geological characteristics and mineralization from the initial drill holes. This visual documentation supports prior exploration results, reinforcing Falcon Gold's exploration strategy and validating geophysical targets identified in previous surveys and historical drilling. With these initial visual results confirming the potential of the Great Burnt camp, Falcon Gold remains committed to advancing its exploration efforts and unlocking further value in the region. #proactiveinvestors #falcongoldcorp #tsxv #fg #otcqb #fgldf GoldExploration #CopperMining #MiningStocks #Newfoundland #JuniorMining #DrillResults #ResourceInvesting #GreatBurnt #NickelMining #GoldInvesting #TSXV

Proactive - Interviews for investors

Tonix Pharmaceuticals secures MCDC grant to advance next-gen Mpox & Smallpox vaccine development

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has been awarded a grant from the Medical CBRN Defense Consortium to support the continued development of its next-generation vaccine candidate. MCDC is a consortium comprising industrial, academic, and non-profit organizations that assist the U.S. government in advancing medical solutions to protect against chemical, biological, radiological, and nuclear threats. Dr. Lederman explained that the vaccine candidate is being developed as an improved immunization option for mpox and smallpox, with the potential for delivery via innovative alternative methods designed to enhance patient compliance, ease of administration, and overall tolerability. The MCDC grant will support comprehensive market analyses, target market identification, and commercialization planning for both private and government sectors. The investigational vaccine is a minimally replicating live-virus formulation based on a modified orthopoxvirus. It has demonstrated the ability to provide single-dose immune protection against mpox in preclinical studies while offering improved tolerability compared to traditional live-virus vaccines. Previous studies have also shown its effectiveness in protecting animals from lethal intratracheal exposure to a more virulent strain of the mpox virus. Tonix is currently preparing for Phase 1 clinical trials in both the United States and Kenya. Kenya, which is on the outskirts of an MPOX outbreak in Africa, presents an opportunity to test the vaccine in an area with a growing case burden. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

Proactive - Interviews for investors

Imugene’s Azercell shows strong response in blood cancer

Imugene Ltd CEO Leslie Chong talked with Kerry Stevenson at Proactive about the FDA's fast-track designation for its immunotherapy candidate, Azercell. The therapy, an allogeneic off-the-shelf CAR-T treatment, has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of blood cancer. Chong highlighted that four out of seven patients treated with Azercell achieved complete response, meaning their cancer was no longer detectable. The longest response duration has now exceeded 11 months. “The FDA has recognised the importance of a product like this and has given us fast-track designation,” Chong stated. The FDA's fast-track status allows Imugene to expedite regulatory discussions and move towards potential commercialization more efficiently. The company sees this as a critical milestone, with Chong emphasising that the priority now is gathering sufficient data to advance towards registration studies. With an estimated 80,000 new DLBCL cases diagnosed annually in the US, Azercell could address a significant unmet need, especially for patients who have exhausted other treatment options. For more updates on Imugene and other biotech innovations, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #Imugene #Biotech #CancerResearch #FDA #CAR_T #Oncology #BloodCancer #DLBCL #MedicalBreakthrough #FastTrack #Immunotherapy

Followers	1
Posts	292
Boards Moderated	0
Alias Born	04/17/2007

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

LMSC Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free